Oxaliplatin-induced fever and release of IL-6.
BACKGROUND
Oxaliplatin is a novel cytotoxic agent with documented activity in colorectal cancer. Side effects are generally moderate, and include peripheral neuropathy along with mild bone marrow suppression and gastrointestinal side effects. To our knowledge, induction of febrile episodes by this agents has not been described in the literature.


METHODS
We present the case of a 74-year-old male patient admitted to our institution for palliative treatment of metastatic colorectal carcinoma. Due to progression during treatment with 5-fluorouracil and leucovorin, chemotherapy consisting of oxaliplatin 85 mg/m(2) on days 1 + 15 plus mitomycin C 8 mg/m(2) on day 1 repeated every 28 days was initiated. The first cycle of this combination was tolerated without side effects, but the patient experienced fever up to 39 degrees C starting 2 h after oxaliplatin administration on day 15 of the second cycle, which persisted for 3 days. Fever again recurred at the same interval following administration of oxaliplatin on day 1 of the next cycle. Blood samples taken at regular intervals disclosed an increase in IL-6 serum levels parallel to the body temperature curve, with the peak corresponding to the highest temperature, while C-reactive protein values remained unchanged. In spite of intensive premedication with steroids, antipyretics and clarithromycin, fever promptly recurred during the third cycle of treatment.


CONCLUSIONS
Our data suggest a clear- cut correlation between fever, the release of IL-6 and oxaliplatin administration. Whether IL-6 release is directly triggered by the application of oxaliplatin or is a bystander phenomenon, however, remains unclear at the moment.
Ulrich-Pur
H
H
Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Austria.
Penz
M
M
Fiebiger
W C
WC
Schüll
B
B
Kornek
G V
GV
Scheithauer
W
W
Raderer
M
M
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000097:blood / Q000188:drug therapy; D005334:Fever / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism*; D008297:Male; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin
D000970:Antineoplastic Agents; D015850:Interleukin-6; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin